(INCY) Incyte - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 19.041m USD | Total Return: 49.8% in 12m
Oncology Drugs, Kinase Inhibitors, Dermatology Creams, Immunotherapies
Total Rating 72
Safety 82
Buy Signal 0.15
Biotechnology
Industry Rotation: -18.1
Industry Rotation: -18.1
Market Cap:
19.0B
Avg Turnover: 117M
Avg Turnover: 117M
Risk 3d forecast
Volatility31.1%
VaR 5th Pctl5.18%
VaR vs Median1.05%
Reward TTM
Sharpe Ratio1.28
Rel. Str. IBD52.9
Rel. Str. Peer Group35.8
Character TTM
Beta0.635
Beta Downside0.600
Hurst Exponent0.484
Drawdowns 3y
Max DD33.83%
CAGR/Max DD0.41
CAGR/Mean DD1.30
EPS (Earnings per Share)
EPS CAGR: 16.83%
EPS Trend: 34.3%
EPS Trend: 34.3%
Last SUE: 1.27
Qual. Beats: 1
Qual. Beats: 1
Revenue
Rev. CAGR: 9.31%
Rev. Trend: 89.3%
Rev. Trend: 89.3%
Last SUE: 1.01
Qual. Beats: 5
Qual. Beats: 5
Warnings
Below Avwap Earnings
Tailwinds
Confidence
Description: INCY Incyte
Incyte Corporation is a Delaware-based biopharmaceutical company specializing in the discovery and commercialization of oncology and inflammation therapies across North America, Europe, and Asia. The company’s portfolio is anchored by JAKAFI, alongside other hematology and oncology treatments such as ICLUSIG, MONJUVI, and PEMAZYRE. Its pipeline includes clinical-stage programs in solid tumors, dermatology, and rare diseases, supported by strategic partnerships with industry leaders like Novartis and Eli Lilly.
The biotechnology sector operates on a high-risk, high-reward business model where significant capital is allocated toward Research and Development (R&D) to secure regulatory approvals. Incyte utilizes a distribution network involving specialty pharmacies and hospital distributors to reach patients requiring targeted kinase inhibitors and immunotherapy treatments. For deeper insights into these market dynamics, you may find further analysis on ValueRay helpful. This industry is characterized by rigorous patent protections, which grant companies temporary market exclusivity to recoup development costs before generic competition enters the market.
- Jakafi revenue concentration creates significant risk ahead of key patent expirations
- Opzelura market penetration in dermatology indications drives top-line growth diversification
- Pipeline execution for povorcitinib determines long-term expansion beyond core oncology portfolio
- Strategic collaborations with Novartis and Lilly influence royalty income and cash flow
- Regulatory approval timelines for expanded indications impact near-term valuation and sentiment
Piotroski VR‑10 (Strict)
7.5
| Net Income: 1.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 14.75 > 1.0 |
| NWC/Revenue: 74.51% < 20% (prev 40.49%; Δ 34.02% < -1%) |
| CFO/TA 0.21 > 3% & CFO 1.52b > Net Income 1.43b |
| Net Debt (-3.97b) to EBITDA (1.87b): -2.12 < 3 |
| Current Ratio: 3.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (206.8m) vs 12m ago 4.36% < -2% |
| Gross Margin: 91.86% > 18% (prev 0.91%; Δ 9.09k% > 0.5%) |
| Asset Turnover: 81.92% > 50% (prev 76.76%; Δ 5.16% > 0%) |
| Interest Coverage Ratio: 759.8 > 6 (EBITDA TTM 1.87b / Interest Expense TTM 2.34m) |
Altman Z''
5.94
| A: 0.54 (Total Current Assets 5.48b - Total Current Liabilities 1.49b) / Total Assets 7.34b |
| B: 0.07 (Retained Earnings 517.1m / Total Assets 7.34b) |
| C: 0.27 (EBIT TTM 1.78b / Avg Total Assets 6.54b) |
| D: 0.30 (Book Value of Equity 539.6m / Total Liabilities 1.79b) |
| Altman-Z'' Score: 5.94 = AAA |
Beneish M
-3.09
| DSRI: 1.05 (Receivables 1.05b/823.1m, Revenue 5.36b/4.41b) |
| GMI: 0.99 (GM 91.86% / 91.16%) |
| AQI: 0.60 (AQ_t 0.15 / AQ_t-1 0.25) |
| SGI: 1.21 (Revenue 5.36b / 4.41b) |
| TATA: -0.01 (NI 1.43b - CFO 1.52b) / TA 7.34b) |
| Beneish M-Score: -3.09 (Cap -4..+1) = AA |
What is the price of INCY shares?
As of May 20, 2026, the stock is trading at USD 95.60 with a total of 1,026,258 shares traded.
Over the past week, the price has changed by -3.56%, over one month by -1.36%, over three months by -6.03% and over the past year by +49.82%.
Over the past week, the price has changed by -3.56%, over one month by -1.36%, over three months by -6.03% and over the past year by +49.82%.
Is INCY a buy, sell or hold?
Incyte has received a consensus analysts rating of 3.67.
Therefor, it is recommend to hold INCY.
- StrongBuy: 8
- Buy: 3
- Hold: 15
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the INCY price?
| Analysts Target Price | 108.5 | 13.5% |
Incyte (INCY) - Fundamental Data Overview
as of 18 May 2026
P/E Trailing = 13.4619 P/E Forward = 12.8041
P/S = 3.5518
P/B = 3.5022
P/EG = 0.3585
Revenue TTM = 5.36b USD
EBIT TTM = 1.78b USD
EBITDA TTM = 1.87b USD
Long Term Debt = 39.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.41m USD (from shortTermDebt, last quarter)
Debt = 43.8m USD (corrected: LT Debt 39.4m + ST Debt 4.41m)
Net Debt = -3.97b USD (recalculated: Debt 43.8m - CCE 4.02b)
Enterprise Value = 15.07b USD (19.04b + Debt 43.8m - CCE 4.02b)
Interest Coverage Ratio = 759.8 (Ebit TTM 1.78b / Interest Expense TTM 2.34m)
EV/FCF = 10.39x (Enterprise Value 15.07b / FCF TTM 1.45b)
FCF Yield = 9.63% (FCF TTM 1.45b / Enterprise Value 15.07b)
FCF Margin = 27.06% (FCF TTM 1.45b / Revenue TTM 5.36b)
Net Margin = 26.71% (Net Income TTM 1.43b / Revenue TTM 5.36b)
Gross Margin = 91.86% ((Revenue TTM 5.36b - Cost of Revenue TTM 436.6m) / Revenue TTM)
Gross Margin QoQ = 91.79% (prev 90.88%)
Tobins Q-Ratio = 2.05 (Enterprise Value 15.07b / Total Assets 7.34b)
Interest Expense / Debt = 1.30% (Interest Expense 569k / Debt 43.8m)
Taxrate = 11.72% (40.3m / 343.6m)
NOPAT = 1.57b (EBIT 1.78b * (1 - 11.72%))
Current Ratio = 3.68 (Total Current Assets 5.48b / Total Current Liabilities 1.49b)
Debt / Equity = 0.01 (Debt 43.8m / totalStockholderEquity, last quarter 5.55b)
Debt / EBITDA = -2.12 (Net Debt -3.97b / EBITDA 1.87b)
Debt / FCF = -2.74 (Net Debt -3.97b / FCF TTM 1.45b)
Total Stockholder Equity = 4.89b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.88% (Net Income 1.43b / Total Assets 7.34b)
RoE = 29.31% (Net Income TTM 1.43b / Total Stockholder Equity 4.89b)
RoCE = 36.05% (EBIT 1.78b / Capital Employed (Equity 4.89b + L.T.Debt 39.4m))
RoIC = 31.97% (NOPAT 1.57b / Invested Capital 4.90b)
WACC = 8.19% (E(19.04b)/V(19.09b) * Re(8.21%) + D(43.8m)/V(19.09b) * Rd(1.30%) * (1-Tc(0.12)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.22 | Cagr: -3.89%
[DCF] Terminal Value 71.58% ; FCFF base≈986.1m ; Y1≈701.0m ; Y5≈375.8m
[DCF] Fair Price = 55.04 (EV 7.02b - Net Debt -3.97b = Equity 11.00b / Shares 199.8m; r=8.19% [WACC]; 5y FCF grow -33.99% → 3.0% )
EPS Correlation: 34.28 | EPS CAGR: 16.83% | SUE: 1.27 | # QB: 1
Revenue Correlation: 89.26 | Revenue CAGR: 9.31% | SUE: 1.01 | # QB: 5
EPS current Quarter (2026-06-30): EPS=1.83 | Chg30d=+3.40% | Revisions=+29% | Analysts=17
EPS next Quarter (2026-09-30): EPS=2.02 | Chg30d=-0.75% | Revisions=-18% | Analysts=17
EPS current Year (2026-12-31): EPS=7.72 | Chg30d=+4.26% | Revisions=+45% | GrowthEPS=+13.6% | GrowthRev=+9.3%
EPS next Year (2027-12-31): EPS=9.05 | Chg30d=+4.64% | Revisions=+39% | GrowthEPS=+17.2% | GrowthRev=+10.8%
[Analyst] Revisions Ratio: +45%